Search

Search Constraints

You searched for: Author/Creator Wiklund, Olov

Search Results

1. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. Issue 2 (28th November 2017)

2. New prospects for PCSK9 inhibition?. (22nd March 2018)

3. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. (February 2020)

4. Corrigendum to "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140–205]. (February 2020)

6. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. (25th March 2014)

9. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). (31st August 2019)

10. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. (27th October 2016)